Incretin Microdosing for Cardiometabolic Health in People With HIV

This study is testing whether very small doses of incretin medications (like GLP-1 drugs used for type 2 diabetes and weight loss) can improve cardiometabolic health — including heart health, weight, and metabolic markers — in people living with HIV who are overweight or have obesity. People with HIV often have higher rates of heart disease and metabolic problems due to the virus and the medications used to treat it. **You may be eligible if...** - You are living with HIV-1 and have been on stable antiretroviral therapy (ART) for at least 24 weeks - Your HIV viral load is undetectable (below 200 copies/mL) - Your BMI is 30 or higher (or 27+ if you have a weight-related health condition) - Any blood pressure, lipid, or blood sugar medications have been at a stable dose for at least 12 weeks **You may NOT be eligible if...** - You have been diagnosed with diabetes (pre-diabetes on stable metformin is okay) - You weigh 400 pounds or more - You have had bariatric or major stomach surgery - You have active severe gastroparesis (stomach-emptying disorder) - You currently use GLP-1 drugs, weight loss medications, or growth hormone Talk to your doctor to see if this trial is right for you.